OMEICOS Therapeutics GmbH - Pipeline


Our clinical candidate OMT-28 is a stable synthetic small molecule analog of the natural omega-3 fatty acid metabolite 17,18-EEQ. Its structure was optimized to provide high efficacy, safety and oral bioavailability. The drug is currently being investigated in clinical phase I. 

Link to our Clinical Phase I trial


RZ PiplineGrafik 1024pxmitSchatten2